Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine.

BACKGROUND: Mizolastine is a nonsedating H1 histamine receptor antagonist with additional antiallergic properties currently marketed in Europe for the treatment of seasonal and perennial allergic rhinitis (PAR) and urticaria. OBJECTIVE: This multicenter, randomized, double-blind, parallel-group study was conducted to evaluate the efficacy and safety of mizolastine in PAR compared with loratadine and placebo. METHODS: After a 1-week placebo run-in period, 428 adult PAR patients received placebo (146 of 428), mizolastine 10 mg (141 of 428), or loratadine 10 mg (141 of 428) once daily for 28 days. Symptoms were evaluated by patients and physicians using a total nasal score, evaluating itching, rhinorrhea, nasal blockade, and sneezing severity. RESULTS: Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0.001) and at the end of the treatment period (-46%, P = 0.01), and significantly greater than that observed with loratadine at D14 (P = 0.031). No significant difference in change in total nasal score was observed between loratadine and placebo at 2- and 4-week visits. The global safety was satisfactory and the incidence of adverse events was similar in the three treatment groups. CONCLUSIONS: Mizolastine provides effective symptom relief in PAR together with a satisfactory safety profile. Improvement with mizolastine was significantly greater than placebo throughout the study despite a large placebo effect. Also mizolastine's effects were greater those observed with loratadine after 2 weeks of treatment.     

Anion selectivity of gamma-aminobutyric acid (GABA) 22,23-dihydroavermectin B1a (DHAVM)-induced conductance changes on locust muscle

Input conductance was recorded from extensor tibia muscle fibres of the locust Schistocerca gregaria. gamma-Aminobutyric acid (GABA; 2.5 X 10(-5) M to 5 X 10(-3) M) and 22,23-dihydroavermectin B1a (DHAVM; 0.01 micrograms/ml, 1.2 X 10(-8) M to 1.0 microgram/ml, 1.2 X 10(-6) M) induced dose-dependent increases in chloride (Cl-) ion permeability on distal muscle fibres. Changing the anion content (Br-, or I- substituted for Cl-) of the saline perfusing the locust muscle fibres induced additional conductance and small hyperpolarizations of the membrane potential. The predominant anion permeability sequences for conductance increases induced by GABA and DHAVM were I- greater than Br- greater than Cl- (n = 5) and Cl- greater than Br- greater than I- (n = 12), respectively. These findings suggest that the anion channel activated by GABA has low selectivity. The irreversible increase in conductance induced by DHAVM appears to involve an ion channel with greater selectivity for Cl-. However, DHAVM-induced changes in filtering properties of a single type of Cl- channel are not precluded. This is consistent with DHAVM action not being dependent on GABA sensitivity of the locust muscle fibres.     

Selective uptake of [3H]glutamine and [3H]glutamate into neurons and satellite cells of dorsal root ganglia in vitro

The uptake of [³H]glutamate and [³H]glutamine into rat dorsal root ganglia has been examined by autoradiography and thin-layer chromatography. [³H]glutamate was selectively accumulated by satellite glial cells and after 10 min, 53% of this had been converted to [³H]glutamine. [³H]glutamine, on the other hand, entered neuronal perikarya and 40% was converted to [³H]glutamate. It is suggested that these selective uptake processes provide supporting evidence for the existence of a neuronal-glial glutamine cycle in dorsal root ganglia. Small dark (B) cells accumulated 6 times as much [³H]glutamine as did large light (A) cells. The reasons for this marked difference in the metabolism of the two main types of dorsal root ganglion neurone are discussed.     

The prevalence of REM-related obstructive sleep apnoea is reduced by the AASM 2012 hypopnoea criteria

Purpose

The variations in reported prevalence of rapid eye movement-related obstructive sleep apnoea (REM-OSA) have been attributed to different definitions, although the effect of hypopnoea criteria has not been previously investigated.

Methods

Within this retrospective study, 134 of 382 consecutive patients undertaking polysomnography (PSG) for the suspicion of OSA met the inclusion criteria. PSGs were scored using both the 2007 AASM recommended hypopnoea criteria (AASM_2007Rec) and the 2012 AASM recommended hypopnoea criteria (AASM_2012Rec). For each hypopnoea criteria, REM-OSA patients were grouped as REM-related [either as REM-predominant OSA (rpOSA) or REM-isolated OSA (riOSA)] or non-stage-specific OSA (nssOSA). Outcome measures (SF-36, FOSQ and DASS-21) were also compared between groups.

Results

Incorporation of the AASM_2012Rec criteria compared to the AASM_2007Rec criteria increased the apnoea-hypopnoea index (AHI) for NREM and REM sleep but decreased the AHI_REM/AHI_NREM ratio from 1.9 to 1.3 (p < 0.001). It also decreased the prevalence of riOSA [15.7 vs 2.2% (p < 0.001) for AASM_2007Rec and AASM_2012Rec, respectively]. The prevalence of rpOSA remained the same for each hypopnoea criteria although the prevalence of nssOSA increased with the AASM_2012Rec hypopnoea criteria [53.0 vs 66.4% (p < 0.006) for AASM_2007Rec and AASM_2012Rec, respectively]. There were no differences in clinical symptoms between the groups, irrespective of hypopnoea criteria used.

Conclusions

This study demonstrates that in comparison with AASM_2007Rec, the AASM_2012Rec hypopnoea criteria reduce the prevalence of riOSA but not rpOSA by reducing the ratio of REM respiratory events and NREM respiratory events.

     

A simple positioning device for radiographic imaging of the patellofemoral joint: a technical note

The informative value of axial radiographs of the patellofemoral joint is highly dependent on application techniques and knee positioning. We developed a simple device that enables an appropriate and easy positioning. With the use of this device, patellofemoral axial radiographs can be obtained at 30 degrees of knee flexion.     

The assessment of constipation in monosymptomatic primary nocturnal enuresis

Objective: Nocturnal enuresis and constipation are common pediatric problems. The aim of this study was to assess the incidence of constipation in children with or without monosymptomatic primary nocturnal enuresis.Methods: The study included 5350 children, ages 5–19 years, who were surveyed to detect the incidence of nocturnal enuresis. Of those surveyed, 679 (12.7%) had primary nocturnal enuresis. All children were questioned by mail with a standard form that addressed their micturition and defecation habits. The children those who had primary nocturnal enuresis were invited to the Pediatric Urology Section of the University Hospital. Of those 679 children, 125 kept that invitation. All 125 of those children underwent an abdominal ultrasound. Also, these children had serum creatinine levels drawn and plain abdominal films taken.Results: Constipation, defined as less than 3 bowel movements per week, was seen in 48 of 679 children with nocturnal enuresis (7.06%). Of those 4671 children without nocturnal enuresis, only 68 (1.45%) had constipation. The difference in constipation between the two groups was statistically significant (z = –9.251; p = 0.000). Of note, 10 of the 125 children (8%), evaluated at the hospital, had constipation. None of the children had an abnormal neurologic examination. Finally, faecal loading was detected on the plain films of 8 of the 125 children evaluated, 7 of who had constipation. The sensitivity of grading plain films for faecal loading to denote constipation in this population was 87.5%.Conclusions: Children with primary nocturnal enuresis should be thoroughly assessed for coexisting constipation.